October Term 2012 · Docket 12-142
Can generic drug makers face design-defect liability despite FDA approval?
The dispute centers on whether federal law blocks state design-defect claims against generic drug manufacturers.
Arguments on 2013-03-19
Showing 1–2 of 2 cases, newest official Court activity first.
October Term 2012 · Docket 12-236
Does the Vaccine Act allow fees for late petitions?
The dispute centers on whether the Vaccine Act permits attorneys to collect fees when a court dismisses a claim for filing too late.